

Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies

Information for the public

Published: 28 February 2023

www.nice.org.uk

Axicabtagene ciloleucel (Yescarta) is available on the NHS. It is a possible treatment for relapsed or refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma in adults who have already had 2 or more systemic therapies.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

These organisations can give you advice and support:

- [Anthony Nolan](#), 0303 303 0303
- [Blood Cancer UK](#), 0808 208 0888
- [Lymphoma Action](#), 0808 808 5555
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-5042-3